Drug stent for rapidly treating intracranial vascular stenosis

Abstract

The invention provides a cutting woven type stent, and belongs to the technical field of medical instruments for treating vascular diseases. The stent comprises an intravascular stent body, a medicine carrying groove used for containing medicine is formed in the outer surface of the intravascular stent body, sustained-release capsules are fixedly distributed in the medicine carrying groove, each sustained-release capsule is provided with a shell, a containing cavity is formed in the shell, and medicine particles and a shell breaking component are loaded in the containing cavities of part of the sustained-release capsules; the medicine assembly for rapidly treating intracranial vascular stenosis further comprises a driving component, and the driving component is arranged in vitro and used for driving the shell breaking component to rapidly break the shell so as to rapidly release medicine particles in the shell. The drug eluting stent is mainly used for solving the technical problem that a drug eluting stent in the prior art cannot quickly release drugs and cannot quickly generate a treatment effect.

Description

Technical Field

[0001] The invention belongs to the technical field of neurointerventional surgery medical equipment, and in particular relates to a drug stent for rapidly treating intracranial vascular stenosis. Background Art

[0002] In the field of medical interventional therapy, drug-eluting stents (DES) are currently widely used to treat intracranial vascular stenosis. DES is a medical device that integrates advanced material science and drug delivery technology. Its core is that a layer of anti-proliferative drugs (such as rapamycin, paclitaxel derivatives, etc.) is covered on the metal stent base. After the stent is successfully implanted in the vascular lesion site, these drugs undergo a gradual release process, aiming to inhibit the excessive proliferation of vascular smooth muscle cells, thereby reducing the incidence of in-stent restenosis (ISR).

[0003] Although DES has shown significant efficacy in reducing ISR, for patients who need urgent symptom control or whose condition worsens, the slow release of drugs by drug-eluting stents cannot produce a rapid therapeutic effect and thus cannot quickly control the condition.

[0004] Therefore, it is necessary to provide an improved technical solution to address the above-mentioned deficiencies in the prior art. Summary of the invention

[0005] The purpose of the present invention is to provide a drug-eluting stent for rapidly treating intracranial vascular stenosis, so as to solve the technical problem in the prior art that drug-eluting stents cannot rapidly release drugs and thus cannot rapidly produce therapeutic effects.

[0006] In order to achieve the above object, the drug stent for rapidly treating intracranial vascular stenosis of the present invention provides the following technical solutions:

[0007] A drug component for rapidly treating intracranial vascular stenosis comprises a vascular stent, wherein the outer surface of the vascular stent is provided with a drug loading groove for containing drugs, wherein sustained-release capsules are fixedly arranged in the drug loading groove, wherein the sustained-release capsules have a shell, wherein the shell has a containing cavity, wherein the containing cavity of some sustained-release capsules is loaded with drug particles and a shell-breaking component, and wherein the drug component for rapidly treating intracranial vascular stenosis further comprises a driving component, wherein the driving component is arranged outside the body and is used to drive the shell-breaking component to rapidly destroy the shell to rapidly release the drug particles in the shell.

[0008] As a further optimized technical solution, the shell breaking component is a magnetic block component, and the driving component is a magnetic device that can attract the shell breaking component.

[0009] As a further optimized technical solution, the block component has a spike portion, and at least the spike portion is magnetic.

[0010] As a further optimized technical solution, at least a hydrophilic polymer coating is provided on the outside of the spike portion. After the shell-breaking component destroys the shell and releases into the blood, the polymer coating reacts rapidly with the water in the blood to generate a buffer layer covering the puncturing component.

[0011] As a further optimized technical solution, the shell breaking component is in the shape of a cone as a whole, and the top of the cone constitutes the spike portion.

[0012] As a further optimized technical solution, the shell breaking component is a quadrangular pyramid as a whole, and the top of the quadrangular pyramid constitutes the spike portion.

[0013] As a further optimized technical solution, the shell breaking component has a brittle coating shell, the interior of the brittle coating shell has a counterweight magnetic block that can be attracted by a magnetic field and a solution for dissolving the sustained-release capsule shell, and the driving component is a magnetic device that can attract the counterweight magnetic block.

[0014] As a further optimized technical solution, the counterweight magnetic block is in the shape of a sphere.

[0015] As a further optimized technical solution, the magnetic device is an electromagnet, which is used to control the magnetic field strength of the electromagnet by controlling the current.

[0016] As a further optimized technical solution, the size of the sustained-release capsule is 150 μm-250 μm, and the length of the shell-breaking component is 60 nm-100 nm.

[0017] Beneficial effects: The present application firstly opens a drug loading groove on the outer surface of the vascular stent, and then fixes a sustained-release capsule containing the drug in the drug loading groove, wherein some of the sustained-release capsules contain a shell-breaking component. When the vascular stent is placed at the position of stenosis of the blood vessel, a driving component is operated outside the patient's body to drive the shell-breaking component to destroy the shell, thereby quickly releasing the drug particles in the sustained-release capsule into the surrounding tissue, thereby achieving rapid treatment of emergency symptoms, and slowly releasing the drug particles at a later stage through some sustained-release capsules that are not loaded with the shell-breaking component, so as to continuously consolidate the treatment position of the patient, thereby ensuring a good treatment effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] The drawings constituting a part of the present application are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. Among them:

[0019] Figure 1 This is a schematic diagram of the overall structure of Embodiment 1 of the present invention;

[0020] Figure 2 This is a schematic diagram of the overall structure of the vascular stent according to Example 1 of the present invention;

[0021] Figure 3 This is a schematic diagram of the overall structure of Embodiment 1 of the present invention;

[0022] Figure 4 This is a schematic diagram of the overall structure of Embodiment 1 of the present invention;

[0023] Figure 5 This is a schematic diagram of the overall structure of Embodiment 1 of the present invention;

[0024] Figure 6 This is a schematic diagram of the overall structure of the sustained-release capsule of Example 2 of the present invention.

[0025] Figure 1-5 Middle: 1. vascular stent; 2. drug loading slot; 3. sustained-release capsule; 301. shell; 302. containing cavity; 303. drug particles; 304a. shell breaking component; 4. driving component;

[0026] Figure 6 Middle: 304b, shell breaking component; 3041, covering shell; 3042, counterweight magnetic block. DETAILED DESCRIPTION

[0027] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. All other embodiments obtained by ordinary technicians in this field based on the embodiments of the present invention belong to the scope of protection of the present invention.

[0028] In the description of the present invention, the terms "longitudinal", "lateral", "upper", "lower", "front", "back", "left", "right", "vertical", "horizontal", "top", "bottom" and the like indicate orientations or positional relationships based on the orientations or positional relationships shown in the accompanying drawings. They are only for the convenience of describing the present invention and do not require that the present invention must be constructed and operated in a specific orientation. Therefore, they should not be understood as limitations on the present invention. The terms "connected" and "connected" used in the present invention should be understood in a broad sense. For example, they can be fixed connections or detachable connections; they can be directly connected or indirectly connected through intermediate components. For ordinary technicians in this field, the specific meanings of the above terms can be understood according to specific circumstances.

[0029] The present invention will be described in detail below with reference to the accompanying drawings and in combination with embodiments. It should be noted that the embodiments and features in the embodiments of the present invention can be combined with each other without conflict.

[0030] According to a specific embodiment of the present invention, the present invention provides a drug component for rapidly treating intracranial vascular stenosis, which is specifically achieved by opening a drug loading groove on the outer surface of a vascular stent, embedding and fixing a sustained-release capsule containing the drug in the drug loading groove, and placing a shell-breaking component for destroying the shell of the sustained-release capsule in some of the sustained-release capsules, and cooperating with a driving component arranged outside the body so that the shell-breaking component punctures the shell of the sustained-release capsule, thereby rapidly releasing the drug into the tissue, thereby facilitating and rapidly controlling the condition.

[0031] Example 1

[0032] like Figure 1 , Figure 2 As shown, the drug component for rapid treatment of intracranial vascular stenosis includes a vascular stent 1. The vascular stent 1 adopts a grid design with a high surface area ratio, such as a closed-loop asymmetric polygonal grid. This design can increase the contact area between the vascular stent 1 and the blood vessel wall, thereby providing more drug release points, which is beneficial to the uniform distribution and rapid release of the drug.

[0033] like Figure 3 , Figure 4 , Figure 5 As shown, the outer surface of the vascular stent 1 is provided with a drug loading groove 2 for containing drugs, and a plurality of sustained-release capsules 3 are fixedly arranged in an inlaid manner in the drug loading groove 2. The sustained-release capsules 3 have a shell 301, and the shell 301 has a accommodating cavity 302 inside. The accommodating cavity 302 of some sustained-release capsules 3 is loaded with drug particles 303 and a shell-breaking component 304a. The drug component for rapidly treating intracranial vascular stenosis also includes a driving component 4, which is arranged outside the body and is used to drive the shell-breaking component 304a to rapidly destroy the shell 301 to quickly release the drug particles 303 in the shell 301.

[0034] In this embodiment, the shell-breaking component 304a is a magnetic block component, and the driving component 4 is a magnetic device that can attract the shell-breaking component 304a. The magnetic device is an electromagnet, which is used to control the magnetic field strength of the electromagnet by controlling the current. When working, the driving component 4 is placed outside the body and acts on the vascular stent 1 in the body in a non-invasive manner (such as close to the scalp or an implanted subcutaneous device).

[0035] Specifically, when in use, the vascular stent 1 is first released at the narrow position of the blood vessel, and then the magnetic device is used to attract the shell-breaking component 304a to impact and destroy the shell 301 of the sustained-release capsule 3, so that the drug particles 303 in the sustained-release capsule 3 are quickly released, first completing the emergency treatment of the location where the condition worsens, and later slowly releasing the drug through the sustained-release capsule 3 without the shell-breaking component 304a, thereby further consolidating the treatment effect.

[0036] In order to further enhance the treatment of seriously diseased blood vessels, more sustained-release capsules 3 containing shell-breaking components 304a may be fixed on the corresponding sections of the vascular stent 1 .

[0037] In order to make the broken shell component 304a pierce the housing 301 of sustained-release capsule 3 more easily, the broken shell component 304a has a spike portion, and the broken shell component 304a can have magnetism as a whole, or at least the spike portion has magnetism. Like this, when the electromagnet works, the attraction spike portion hits towards the housing 301 of sustained-release capsule 3, thereby more easily damaging the housing 301. In the present embodiment, the broken shell component 304a is a cone shape as a whole, and the spike portion formed by the top of the cone, in other embodiments, the broken shell component 304a as a whole can also be a quadrangular pyramid, the spike portion formed by the top of the quadrangular pyramid, or the broken shell component 304a is a structure with a vertex such as a polygonal pyramid.

[0038] Further, the size of the sustained-release capsule 3 is 150 μm-250 μm (for example, it can be 150 μm, 160 μm, 170 μm, 180 μm, 190 μm, 200 μm, 210 μm, 220 μm, 230 μm, 240 μm, 250 μm and any interval between the two end points), the length of the shell-breaking component 304 is 60 nm-100 nm (for example, it can be 60 nm, 70 nm, 80 nm, 90 nm, 100 nm and any interval between the two end points), and the sustained-release capsule 3 is 150 μm-250 μm (for example, it can be 150 μm, 160 μm, 170 μm, 180 μm, 190 μm, 200 μm, 210 μm, 220 μm, 230 μm, 240 μm, 250 μm and any interval between the two end points). The size of the capsule 3 and the shell-breaking component 304a is relatively small. The shell-breaking component 304a with the spike portion is directly released into the blood vessel without causing adverse damage to the blood vessel. However, in order to further ensure the safety of the blood vessel, a hydrophilic polymer coating can be provided on the shell-breaking component 304a as a whole, or at least a hydrophilic polymer coating can be provided on the outside of the spike portion, such as hydrophilic polymer materials such as polyvinyl pyrrolidone (PVP), polyacrylamide (PAM), polyethylene glycol (PEG), polyvinyl alcohol (PVA), natural polysaccharides and derivatives. In this way, when the shell-breaking component 304a destroys the housing 301 and is released into the blood, the polymer coating reacts rapidly with the water in the blood to generate a buffer layer that covers the puncturing component, and the buffer layer helps to reduce the blood turbulence and eddy current caused by the explosion, thereby reducing the impact and damage to the blood vessel wall. Then the shell-breaking component 304a is finally discharged from the body with the normal circulation of blood.

[0039] Example 2

[0040] This embodiment provides another form of shell breaking component. Specifically, other technical solutions in this embodiment are the same as those in Embodiment 1 and are not described in detail herein.

[0041] In this embodiment, if Figure 6As shown, the shell breaking component 304b has a brittle coating shell 3041, and the interior of the brittle coating shell 3041 has a counterweight magnetic block 3042 that can be attracted by a magnetic field and a solution for dissolving the shell 301 of the sustained-release capsule 3, and the driving component 4 is a magnetic device that can attract the counterweight magnetic block 3042.

[0042] In this way, when the vascular stent 1 is released at the narrow position of the blood vessel, the magnetic device attracts the counterweight magnetic block 3042 carrying the shell-breaking component 304b to collide with the shell 301 of the sustained-release capsule 3 as a whole, and then the brittle coating shell 3041 breaks, and the solution inside it for dissolving the shell 301 of the sustained-release capsule 3 flows out and quickly dissolves the shell 301 of the sustained-release capsule 3, thereby facilitating the release of the drug particles 303 from the shell 301 to quickly suppress the disease.

[0043] Furthermore, in order to prevent the weighted magnetic block from damaging the blood vessels, the weighted magnetic block 3042 is designed to be spherical. At the same time, the covering shell 3041 is also coated with a hydrophilic polymer coating of the same material as in Example 1. In this way, when the covering shell 3041 is broken into pieces and enters the blood, the polymer coating reacts quickly with the water in the blood to form a buffer layer covering the puncturing part, which helps to reduce the damage of the covering shell 3041 fragments to the blood vessels.

[0044] In summary, the present application firstly opens a drug loading groove 2 on the outer surface of the vascular stent 1, and then fixes a sustained-release capsule 3 containing the drug in the drug loading groove 2, wherein some of the sustained-release capsules 3 contain shell-breaking components 304a, 304b. When the vascular stent 1 is placed at the position of vascular stenosis, the shell-breaking components 304a, 304b are driven by operating the driving component 4 outside the patient's body to destroy the shell 301, thereby quickly releasing the drug particles in the sustained-release capsule to the surrounding tissue, thereby achieving rapid treatment of emergency symptoms, and slowly releasing the drug particles in the later stage through some sustained-release capsules that are not loaded with shell-breaking components to continuously consolidate the treatment position of the patient, thereby ensuring a good treatment effect.

[0045] It should be understood that the above description is merely exemplary and the embodiments of the present application do not limit this.

[0046] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention are within the scope of protection of the pending claims of the present invention.

Claims

1. A drug component for rapidly treating intracranial vascular stenosis, comprising a vascular stent (1), characterized in that: The outer surface of the vascular stent (1) is provided with a drug loading groove (2) for containing drugs, and a sustained-release capsule (3) is fixedly arranged in the drug loading groove (2). The sustained-release capsule (3) has a shell (301), and the shell (301) has a containing cavity (302) inside. The containing cavity (302) of some sustained-release capsules (3) is loaded with drug particles (303) and shell-breaking components (304a, 304b). The drug component for rapidly treating intracranial vascular stenosis also includes a driving component (4), and the driving component (4) is arranged outside the body and is used to drive the shell-breaking components (304a, 304b) to rapidly destroy the shell (301) so as to quickly release the drug particles (303) in the shell (301).

2. The drug component for rapidly treating intracranial vascular stenosis according to claim 1, characterized in that: The shell breaking component (304a) is a block-shaped component with magnetism, and the driving component (4) is a magnetic device capable of attracting the shell breaking component (304a).

3. The drug component for rapidly treating intracranial vascular stenosis according to claim 2, characterized in that: The block-shaped component has a spike portion, and at least the spike portion has magnetism.

4. The drug component for rapidly treating intracranial vascular stenosis according to claim 3, characterized in that: At least a hydrophilic polymer coating is provided on the outside of the spike portion, and after the shell-breaking component (304a) destroys the shell (301) and is released into the blood, the polymer coating reacts rapidly with the water in the blood to generate a buffer layer covering the puncturing component.

5. The drug component for rapidly treating intracranial vascular stenosis according to claim 3, characterized in that: The shell breaking component (304a) is in the shape of a cone as a whole, and the top of the cone constitutes the spike portion.

6. The drug component for rapidly treating intracranial vascular stenosis according to claim 3, characterized in that: The shell breaking component (304a) is in the form of a quadrangular pyramid as a whole, and the top of the quadrangular pyramid constitutes the spike portion.

7. The drug component for rapidly treating intracranial vascular stenosis according to claim 1, characterized in that: The shell breaking component (304b) has a brittle coating shell (3041), the interior of the brittle coating shell (3041) has a counterweight magnetic block (3042) that can be attracted by a magnetic field and a solution for dissolving the shell (301) of the sustained-release capsule (3), and the driving component (4) is a magnetic device that can attract the counterweight magnetic block (3042).

8. The drug component for rapidly treating intracranial vascular stenosis according to claim 7, characterized in that: The counterweight magnetic block (3042) is in the shape of a sphere.

9. The drug component for rapidly treating intracranial vascular stenosis according to claims 2-8, characterized in that: The magnetic device is an electromagnet, which is used to control the magnetic field strength of the electromagnet by controlling the current.

10. The drug component for rapidly treating intracranial vascular stenosis according to any one of claims 1 to 8, characterized in that: The size of the sustained-release capsule (3) is 150 μm-250 μm, and the length of the shell-breaking component (304) is 60 nm-100 nm.

Images